Status:
COMPLETED
Depression And Bipolar Disorder
Lead Sponsor:
GlaxoSmithKline
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is an 8-week evaluation of an investigational drug for treating depression in bipolar patients. Depressed patients will be given either an investigational drug or placebo and receive psychi...
Eligibility Criteria
Inclusion
- Inclusion
- Patients must provide written and informed consent.
- Diagnosis of Bipolar II Disorder and currently depressed for minimum of the last 8 weeks.
- Exclusion
- Patients must not be suicidal.
- Patients must not have a history of non-response to antidepressant treatment.
- Patients must not have a clinical history of substance dependence in the past year or abuse within the 4 weeks prior to study entry.
- Patients must not have had epilepsy or hypothyroidism.
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT00274677
Start Date
November 1 2003
End Date
August 1 2005
Last Update
September 15 2016
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Burbank, California, United States, 91506
2
GSK Investigational Site
Loma Linda, California, United States, 92354
3
GSK Investigational Site
San Diego, California, United States, 92108
4
GSK Investigational Site
Marietta, Georgia, United States, 30060